High Throughput Cardiotoxicity Assays Using Stem Cell-Derived Cardiomyocytes

Cardiac toxicity is responsible for a large percentage of new drugs that fail in clinical trials. The development of highly predictive in vitro assays suitable for high throughput screening is critical to improve the inefficiencies and high costs associated with cardiac safety compound failure. This application note demonstrates a method for quickly and easily characterizing cardiotoxic compounds using stem cell-derived cardiomyocytes.